Myelodysplastic Syndromes (MDS)

A Guide for Patients

Leukaemia Care
YOUR Blood Cancer Charity
Introduction

Being diagnosed with a myelodysplastic syndrome (MDS) can be a shock, particularly when you may never have heard of it. This booklet has been written to help you understand more about MDS. It describes what the various forms are, how they are diagnosed and treated and also the expected outcome (prognosis). It will also provide information on coping with the emotional impact of an MDS diagnosis.

For more information, your haematologist or clinical nurse specialist will be able to provide advice that is specific to your diagnosis.

This booklet has been written by Dr Sally Killick, Consultant Haematologist; Dr Dominic Culligan, Consultant Haematologist; Philip Alexander, Counsellor and Cognitive Behaviour Psychotherapist; Geke Ong and Janet Hayden, Clinical Nurse Specialists; and peer reviewed by Professor David Bowen, Honorary Professor of Myeloid Leukaemia Studies and Consultant Haematologist at St James’s Institute of Oncology. The booklet has also been reviewed by patients and we are grateful to Chris Dugmore and Claudia Richards for their valuable contribution.

Throughout this booklet you will see a number of quotations. These are the real experiences of MDS patients and will hopefully help you to understand your situation a bit better.

If you would like any information on the sources used for this booklet, please email communications@leukaemiacare.org.uk for a list of references.
In this booklet

Introduction 2

In this booklet 3

Acknowledgements 4

About Leukaemia Care 6

MDS at a glance 10

Who gets MDS and why? 12

Signs and symptoms 13

Diagnosis 14

What are the types of MDS? 17

What is the prognosis of MDS? 19

Treatment of MDS 22

The psychological impact of MDS 33

Living with MDS 44

MDS specialist centres and other useful organisations 53

Glossary 58

Appendix 60
Acknowledgements

This booklet has been compiled by MDS UK Patient Support Group, Leukaemia Care and Bloodwise in a joint collaboration. Although you are reading the version supplied by Leukaemia Care, all of the wording is the same in each organisation’s booklet. This booklet does not endorse any specific product or brand – any names mentioned are for information only.

Acknowledgements and further thanks to The Irish Cancer Society for their permission to use information and images from their MDS booklet.

This booklet has been endorsed by the Leukaemia & Lymphoma NI charity.

Leukaemia & Lymphoma NI funds research into the causes and cures of leukaemia, lymphoma and myeloma in Northern Ireland.

Contributing charities

About MDS UK
MDS UK Patient Support Group provides information, assistance and advice to patients and families affected by myelodysplastic syndromes. We offer a helpline, newsletter, website, chat forum and meeting groups nationwide to facilitate contact with other MDS patients and their families. Based at King’s College Hospital, MDS UK is the only national support group solely dedicated to MDS.

About Leukaemia Care
Leukaemia Care is dedicated to providing information, support and advice to blood cancer patients, their carers and loved ones.

Whether they need a listening ear from our Patient Advocacy team, a buddy to chat to who has been in a similar position, a visit to one of our support groups or good quality, trusted information about a diagnosis, treatment or side effects, we are here for them all.

About Bloodwise
We’re the UK’s leading blood cancer research charity. We fund research to improve treatment
and care for people living with all types of blood cancer, and we provide anyone affected with information and support.
About Leukaemia Care

Leukaemia Care is a national charity dedicated to ensuring that people affected by blood cancer have access to the right information, advice and support.

Our services

Helpline
Our helpline is available 9.00am - 10.00pm on weekdays and 9.00am - 12.30pm on Saturdays. If you need someone to talk to, call 08088 010 444

Nurse service
We have two trained nurses on hand to answer your questions and offer advice and support, whether it be through emailing nurse@leukaemiacare.org.uk, over the phone on 08088 010 444 or via LiveChat.

Patient Information Booklets
We have a number of patient information booklets like this available to anyone who has been affected by a blood cancer. A full list of titles – both disease specific and general information titles – can be found on our website at www.leukaemiacare.org.uk/support-and-information/help-and-resources/information-booklets/

Support Groups
Our nationwide support groups are a chance to meet and talk to other people who are going through a similar experience. For more information about a support group local to your area, go to www.leukaemiacare.org.uk/support-and-information/support-for-you/find-a-support-group/

Buddy Support
We offer one-to-one phone support with volunteers who have had blood cancer themselves or been affected by it in some way. You can speak to someone who knows what you are going through. For more information on how to get a buddy call
08088 010 444 or email support@leukaemiacare.org.uk

Online Forum
Our online forum, www.healthunlocked.com/leukaemia-care, is a place for people to ask questions anonymously or to join in the discussion with other people in a similar situation.

Patient and carer conferences
Our nationwide conferences provide an opportunity to ask questions and listen to patient speakers and medical professionals who can provide valuable information and support.

Website
You can access up-to-date information on our website, www.leukaemiacare.org.uk, as well as speak to one of our care advisers on our online support service, LiveChat (9am-5pm weekdays).

Campaigning and Advocacy
Leukaemia Care is involved in campaigning for patient well-being, NHS funding and drug and treatment availability. If you would like an update on any of the work we are currently doing or want to know how to get involved, email advocacy@leukaemiacare.org.uk

Patient magazine
Our quarterly magazine includes inspirational patient and carer stories as well as informative articles by medical professionals. To subscribe go to www.leukaemiacare.org.uk/communication-preferences/
## Your details:

<table>
<thead>
<tr>
<th>Date of diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>My diagnosis/type of MDS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

## Cytogenic results

<table>
<thead>
<tr>
<th>Date</th>
<th>Details and chromosome affected</th>
<th>Good, normal or poor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Contact details</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>Consultant haematologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specialist nurse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematology day care unit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematology inpatient ward</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emergency contact number</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Myelodysplastic syndromes at a glance

What are myelodysplastic syndromes?
The myelodysplastic syndromes, or MDS for short, are a group of diseases in which the production of blood cells by the bone marrow is faulty. It is a type of cancer and sometimes may be referred to as bone marrow failure. The bone marrow is located inside some of your bones and it is the factory where blood cells are made. It is here where the problem lies.

The bone marrow makes three main types of blood cells:

1. Red blood cells that carry oxygen around the body
2. White blood cells that fight infections
3. Platelets that prevent bleeding

What causes MDS?
In MDS, the bone marrow is usually more active than normal, yet the blood cells it produces are not healthy (we refer to that as ‘dysplastic’); do not work as well as they should and many die either before they reach the bloodstream or shortly afterwards.

This results in the number of blood cells in the bloodstream being reduced. This is referred to as a ‘cytopenia’. Some patients have just one type of blood cell that is low (such as red blood cells), however, sometimes MDS can cause a reduction in all the types of blood cells. When this occurs, it is called ‘pancytopenia’.

Can MDS lead to any other conditions?
In addition to low blood counts, the myelodysplastic syndromes share a common tendency to develop into acute myeloid leukaemia (AML) over time. In MDS, the bone marrow has a number of immature abnormal cells called blasts. In some patients with MDS the number of blasts increases with time. Leukaemia (AML) is defined as having more than 20% blast cells.

The risk of AML occurring depends on the type of MDS, but some patients may never progress to AML.

You can find out more about AML in factsheets and booklets available from Bloodwise and Leukaemia Care.
Is MDS a cancer?

MDS is a form of bone marrow cancer, although its progression into leukaemia does not always occur. It is included in the World Health Organisation Classification of Haematopoietic (blood and bone marrow) Tumours.

You do not need to learn everything about MDS at once. You can keep this booklet and refer back to it, reading different sections as and when you’re ready.
Who gets MDS and why?

MDS is a rare disease. It may be diagnosed at any age but it is very rare in children and young adults. This booklet deals with MDS occurring in adults.

The typical age for patients to develop MDS is around 75 years old. About 9 out of 10 patients are over 50 years at the time of diagnosis. Men are slightly more likely than women to be diagnosed with MDS.

The cause of MDS remains largely unknown, although there are many research groups around the world who are trying to improve our understanding of why it occurs and in whom. There are certain factors that may increase your chance of developing MDS and these include:

- **Previous chemotherapy with or without radiotherapy** - this treatment may have been given in the past (usually for other cancers). It is thought that the treatment damages the bone marrow and may cause MDS in some patients. This is called secondary or therapy-related MDS, as it is secondary to the previous chemotherapy or radiotherapy.

- **Inherited disorders** - very rarely, MDS can be inherited or may develop from another rare blood disorder. For this reason, young patients may be tested for any diseases that are linked to MDS. However, for the vast majority of patients, MDS will not be passed down to children and is not an inherited genetic disease.

- **Environmental factors** - exposure to toxic chemicals such as benzene may marginally increase the risk of MDS, but such exposure is now uncommon.

MDS is not an infectious disease and it cannot be passed on to other people.
What are the signs and symptoms of MDS?

Symptoms vary from person to person and depend on which blood cells have become reduced in your bloodstream. About 8 in 10 patients have anaemia, whilst about 2 in 10 present to their doctor with infections or bleeding.

Anaemia is due to a lack of red blood cells (also referred to as low haemoglobin), which may lead to fatigue and shortness of breath, even on light exertion.

“When I was diagnosed I was surprised; I had not heard of MDS before. But I also felt relieved; a reason why I was so fatigued.”

When your platelet count is low, you can suffer from easy bruising and bleeding. This can sometimes manifest itself as a rash on your skin. These are tiny bleedings under the skin called petechiae and often appear where clothes are tight fitting like around the ankles or waist. Nose or gum bleeds can also be a sign of a low platelet count.

Recurrent and persistent infections are another common symptom of MDS due to low white blood cell counts.

Some MDS patients have no signs or symptoms and are diagnosed by chance as a result of a routine blood test.

Anaemia is the most commonly experienced symptom in MDS.
Diagnosis

How are the myelodysplastic syndromes diagnosed?

Full blood count
Low blood counts are picked up by a simple test called a full blood count (FBC). The laboratory performing the test will then examine the blood cells on a slide (called a blood film) under the microscope. If you are found to have changes on the blood film that suggest MDS, you will usually be referred to a blood specialist (haematologist). It is important to rule out other causes of a low blood count so the doctor will ask general health questions and give you a physical examination.

Bone marrow test
As MDS is a disease of the bone marrow, a bone marrow test is usually needed to diagnose the condition or monitor response to treatment.

What does a bone marrow test involve?
This is usually performed as an outpatient, meaning you don’t need to stay in hospital overnight and can go home after the procedure. A small liquid bone marrow sample is taken followed by a biopsy, generally from the pelvis. The doctor will numb the area with local anaesthetic and insert a needle into the bone marrow cavity in order to take the sample. The procedure usually takes around 20-30 minutes, but you should allow an hour of your time. It may be uncomfortable at the time, or later that evening, but simple paracetamol is usually enough to relieve the pain. You may be asked to lie on your back after the procedure for 10 minutes to reduce the risk of bleeding.
A small dressing or plaster is applied to the site.

"I remember very little from when I was diagnosed as I was terrified and in shock."

**How long do I have to wait for the results?**

Preparing the sample and analysing all the results can take two to three weeks. The bone marrow sample is examined by a doctor under a microscope to look for changes seen in MDS. Additional tests are often requested on the bone marrow sample, which may help to make the diagnosis and provide information about how the disease will behave (prognosis).

These tests include cytogenetics (sometimes called a ‘karyotype’), which is the study of the changes in the structure of the chromosomes in the affected cells. In addition, there is a general move towards molecular testing (to look for DNA mutations), which we hope will lead to more precision and therefore make care more personalised. However, at the moment we are still learning what the molecular changes may mean for MDS patients.

If the bone marrow changes are not clear and there is doubt about whether or not you have MDS, your doctor may decide to monitor your blood counts and repeat the bone marrow test at a later stage.

A bone marrow sample may not be necessary in some cases, for example if the results are unlikely to affect treatment decisions for the person.
Diagnosis (cont.)

Waiting for your test results may be an anxious time. Talk to your family and friends or contact patient support organisations which can assist in different ways. They can help put you in touch with other patients over the phone, in person or through online forums.

You can read about the experiences of other people who are going through or have been through something similar on the websites of patient support organisations. It is important at an early stage to get support and information from recommended and reputable sources, as the internet can present misleading and unvetted information.

“There is a lot of confusing and scary literature around, so talk with real people about it; it’s really helpful.”

You can find details of all the different support organisations in Chapter 10: MDS specialist centres and other useful organisations.
Your doctor will describe the type of MDS that you have, as each type can behave differently. The World Health Organization (WHO) has developed a regularly updated classification for separating the different types of MDS. This was updated in 2016, and replaces the older classification of MDS in 2008. Both classifications may still be referred to and therefore the old classification can be seen as an Appendix at the end of the booklet. This system is based on the blood results, the appearance of the bone marrow, the number of abnormal immature blast cells and any chromosome changes found. The immature cells are called blasts, which may be increased in some of the types of MDS.

There are six broad types of MDS included in the current 2016 classification. These are:

1. MDS with single lineage dysplasia (MDS-SLD)
2. MDS with multilineage dysplasia (MDS-MLD)
3. MDS with ring sideroblasts (MDS-RS)
4. MDS with excess blasts (MDS-EB); MDS-EB-1 and MDS-EB-2
5. MDS, unclassifiable (MDS-U)
6. MDS with isolated del(5q) or with 1 additional abnormality

Please note: Information on CMML (chronic myelomonocytic leukaemia) is available as a separate booklet, as it now falls under the WHO 2016 category of ‘Myelodysplastic/Myeloproliferative neoplasms’.
What are the types of MDS? (cont.)

There are many types of MDS and this can be difficult to understand. Spend time talking to your doctor or nurse so you understand how your MDS will be treated. It’s important that you know and understand your exact diagnosis. You could ask your treatment team to write it in the front of this booklet, so that you have it to hand.

The terminology used can be difficult to understand, so ask your doctor to explain which type of MDS you have. Dysplasia means that the bone marrow cells are abnormal in their appearance. Sideroblasts are young red blood cells that have a very distinctive ring of iron granules seen under the microscope. MDS with isolated del(5q) means the chromosome tests show part of chromosome 5 is missing.

What does high risk and low risk MDS mean?

It is often easier to consider whether the type of MDS you have falls into what is called a LOW risk group or a HIGH risk group. The ‘risk’ refers to your chance of developing acute myeloid leukaemia (AML) and your life expectancy (survival). In the low risk disease group a patient has about a 1 in 10 chance of progressing to AML. The low risk group includes MDS-SLD, MDS-MLD, MDS-RS, MDS-U and MDS with del(5q) either in isolation or with 1 additional abnormality. In contrast, the risk of developing leukaemia is greater in the high risk disease group (MDS-EB). The separation into these groups is important as the treatment of patients with low risk and high risk disease can differ. Your doctor may use the WHO classification to decide whether your disease is low or high risk; although it is usually better to use the prognosis score discussed next.
What is the prognosis of MDS?

Prognosis refers to the expected outcome or survival from MDS and is therefore different from classification. Your prognosis can depend on many factors, including those not related to MDS, such as your general fitness and age. However, to allow your doctor to make the right treatment decisions, MDS doctors and scientists around the world have designed a number of scoring systems to help predict how your MDS is likely to behave. Over time, these scoring systems have evolved to give more accurate estimations. The most commonly used scoring system is the revised International Prognostic Scoring System (IPSS-R). This replaces the previous IPSS.

Can you explain the scoring systems in more detail?

The British Society of Haematology MDS Guidelines recommend using the IPSS-R as a scoring system (see appendix).

The IPSS-R score is calculated from:

- Your blood count results at the time your MDS is diagnosed
- The number of abnormal immature cells (blasts) in your bone marrow at diagnosis
- The chromosome test results from your bone marrow at diagnosis

The calculator adds together the individual scores to give a final score, which puts you into one of the following IPSS-R risk groups:

- Very low
- Low
- Intermediate
- High
- Very high

The risk groups describe the expected risk of developing acute myeloid leukaemia (AML) and expected survival. This helps your doctor to identify and discuss with you the best treatment choices for you as an individual. For more information about the risk and survival predicted in each group, see page 62 [appendix]. It is important to understand that the expected outcomes for each group give an
What is the prognosis of MDS? (cont.)

an indication of what may happen in that group of patients as a collective. This gives a useful framework for a discussion about the future and the options for treatment, but it is not possible to give a precise outcome figure for an individual patient. As our understanding of the molecular changes seen in MDS increases, this may allow us to more accurately work out an individual patient’s outcome and guide treatment further.

Doctors sometimes refer to ‘low risk’ and ‘high risk’ MDS. If doctors are using the older IPSS, ‘low risk’ refers to patients with Low and Intermediate-1 categories, whilst ‘high risk’ refers to patients with IPSS Intermediate-2 and High categories. The risk designation is more difficult with the more recent IPSS-R, ‘low risk’ certainly including Very Low and Low categories and ‘high risk’ including High and Very High categories. As yet, the risk designation for the IPSS-R Intermediate group has not been confirmed.

UK MDS Forum and British Society of Haematology (BSH) MDS Guidelines

A group of expert haematologists, with a specialist interest in MDS, has prepared guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. These are updated periodically to reflect changes in medical practice. The content of the treatment section of this booklet is based on the BSH guidelines, the full version of which can be found online at www.b-s-h.org.uk/guidelines

It is important to understand that although guidelines represent the collected opinions of a group of experts based on best clinical practice from available evidence, they are only guidelines. In most cases, a patient’s treatment will be based on these but a doctor may decide that it is not in the best interests of a specific patient to be treated exactly, or even broadly, according to the guidelines. If this is the case for you, then your doctor will discuss
the reasons for this.

The UK MDS Forum is an expert organisation open to those healthcare workers and scientists with an interest in MDS. The aim of the forum is to increase the awareness of MDS through education and increase access to clinical trials for patients with MDS across the UK.
How is MDS treated?
The way that MDS behaves varies from person to person, and depends on the type of MDS that you have. The types of MDS have been described in detail earlier in this booklet. Treatment is based on British Guidelines agreed by MDS specialists, and your care will be discussed in your local multidisciplinary team (MDT) meeting.

What is an MDT?
Your diagnosis and treatment will be discussed and reviewed by a team of clinical specialists including haematologists in your local area. They are called your multidisciplinary team (MDT). They hold regular meetings which allow your case to be discussed by many doctors and healthcare professionals in the Haematology clinical team. It may also be necessary to ask for an opinion outside of this group to help either with the diagnosis or to discuss the best form of treatment.

The MDT meetings involve doctors, nurses and other healthcare professionals putting their heads together and deciding the best treatment specifically for you.

Treatment planning
Once the diagnosis of MDS has been made, you and your doctors will decide on the best treatment for you. The treatment that you are offered will depend on the type of MDS you have, your own wishes, your age, your general wellbeing or fitness and the IPSS-R score, or in some cases the IPSS score (see earlier section). Before your treatment starts, your doctor or nurse will explain the benefits and side effects of the chosen treatment so that you can give your consent. It is likely that you will need to sign a consent form to agree to the treatment. If you are unsure about anything, do ask, as MDS is a complicated disease to understand. The BSH MDS guidelines recommend that all patients who are newly diagnosed with MDS are discussed with a
regional or national expert in MDS given that the disease is rare. You are entitled to ask your doctor if they have done this. The NHS also allows you to ask to see a regional or national expert in MDS if you think that this would help you.

Not all patients need active treatment, as some do not have any symptoms. If you are not starting treatment, you will have regular check-ups which is often referred to as ‘watch and wait’ or ‘active monitoring’.

"The challenge is predominantly mental since it’s very hard to accept that I have cancer but that it isn’t being treated."

Broadly speaking, treatment of MDS will include one or more of the following:

- **Supportive care** – this aims to control the symptoms of MDS
- **Non-intensive treatment** – this treatment tries to slow down the progression of MDS and improve your blood counts
- **Intensive chemotherapy** – this involves giving high doses of chemotherapy in hospital
- **Stem cell transplant** – this gives your body new stem cells so it can grow new healthy blood cells in the bone marrow

Unfortunately, most patients’ MDS cannot be cured but MDS can usually be controlled and often improved.

The first question that your doctor will ask themselves is whether there is a treatment option that has a chance of curing the MDS. The only treatments that can possibly cure MDS are either a stem cell or bone marrow transplant from another person or, very rarely, intensive chemotherapy.

If a stem cell transplant is an option for you, you will be identified early so that a search for donors can be started and a transplant considered at an early stage.

**What is a clinical trial?**

Research into MDS continues worldwide to improve our knowledge of why MDS occurs, how individual types of MDS behave and how best to treat the condition. Today we benefit from the thousands of patients who have been part of clinical trials and research studies in the past. The words ‘research’, ‘trial’ or ‘new
Treatment of MDS (cont.)

Drug’ sometimes scare people, but rest assured, patients receiving new drugs in a trial are monitored very closely for side effects. Your doctor may discuss with you a clinical trial available at your hospital; however, you cannot be entered into a trial without your permission. The trial needs to be fully explained to you, and you need to have time to think about the treatment before deciding. This is called ‘informed consent’. If you agree to be treated in a clinical trial, you can still change your mind at any point and come out of the trial. If you decide not to go into a clinical trial, you will be given the best-proven treatment available. Please ask if there are any clinical trials suitable for you available in your hospital or at your nearest specialist centre.

Supportive care

All patients will need supportive care at some stage, either alone or to support other treatments being given. Supportive care is not directed at the underlying disease but rather at controlling the symptoms and complications caused by the disease. The nature and extent of supportive care needed depends on which blood cells are affected and exactly how low the blood levels fall. Most patients will need blood transfusions at some stage.

Treating anaemia

Most patients (but not all) diagnosed with MDS are anaemic. This can cause symptoms such as tiredness and shortness of breath, affecting your quality of life. Some patients continue having a normal or reasonable quality of life despite anaemia and so will not necessarily need treatment for the anaemia at that stage. Other patients will need blood transfusions to improve the symptoms caused by the anaemia. The haemoglobin (Hb) level in your blood results will show your level of anaemia.
**Growth factors**

Blood cell numbers can sometimes be increased by the use of growth factors. Growth factors are like natural ‘hormones’ that stimulate our blood production. We all make these growth factors every day. For example, erythropoietin (sometimes known as ‘EPO’) is a growth factor that increases red blood cell numbers. Granulocyte-colony stimulating factor (or ‘G-CSF’) increases white blood cell numbers. Not all patients are suitable for this treatment, and only some MDS patients will respond. Your doctor can advise you on your suitability for growth factors. EPO is considered a safe treatment in MDS.

Growth factors are given as an injection under the skin. The number of injections needed will vary from patient to patient. A district nurse can give the injections, or you (or a family member) can learn how to give the injections yourself. The skin around the injection site may become irritated, so it is best to regularly change the injection site. Do talk to your nurse(s) about this and also the common side effects that you may expect.

**Blood transfusions**

Blood transfusions are a very important part of your care. They will be considered if you have symptoms from anaemia. There is no set haemoglobin level at which a blood transfusion is given, but your doctor will assess your symptoms and you will decide together. The frequency of transfusions will vary between patients; some need transfusions every few months whilst others need one every couple of weeks. Usually, once you have started having regular blood transfusions, the length of time between transfusions will gradually get shorter. If you find that your symptoms of anaemia come back well before your next transfusion is due, contact your Haematology team and discuss whether the interval between transfusions should be shorter, or the number of units of blood increased. This varies between patients. An improvement in your symptoms after having a transfusion may not be immediate, sometimes it can take a few days to start feeling the benefit.
Treatment of MDS (cont.)

It is important that you are transfused adequately to control your symptoms as it will help your quality of life. Discuss this with your haematology team.

With every unit of blood you receive from a transfusion, you will receive an excess amount of iron. Over time this can build up in your body and may possibly cause damage to certain organs, like your heart or liver. Because blood transfusions are rich in iron, it is important that you do not take additional iron tablets unless your doctor prescribes them. There is still uncertainty about whether too much iron in your body is always harmful. The level of iron in the body will be regularly checked if you are on regular transfusions and treatment will be considered if there is a build-up of excess iron. This treatment is called iron chelation; however, there remains uncertainty about the benefits of removing iron. Whether you are offered iron chelation therapy or not will depend on the likely benefits versus the likely disadvantages in your individual case. This will be discussed with you before you make a decision to start iron chelation. It is important that you do not reduce the number of blood transfusions you receive due to the concern about your iron levels, as this may not adequately control your symptoms.

Desferal (deferoxamine) is a drug used to treat the build-up of excess iron and is given as a continuous subcutaneous injection under your skin by a pump. There are special teams that can teach you how to administer the drug at home. Exjade is another iron chelator and comes in tablet form. However, in most cases this is only available for patients who cannot tolerate subcutaneous Desferal, who have serious side effects on Desferal or where it is thought not to be working adequately. Both treatments can have certain side effects and often need to be continued for a long period of time to be effective. Your doctor can discuss this with...
you. Don’t hesitate to discuss your iron levels with your doctor at any time during your treatment.

"Having a blood transfusion is an amazing feeling. People around me could see the colour returning to my face. I had a shower and danced because at last it no longer hurt to stand and wash my hair. The relief was immediate."

**Platelet transfusions**

About half of MDS patients will have a reduced platelet count at diagnosis (this is called thrombocytopenia). The platelets may also function poorly and this means that bruising and bleeding can sometimes be a serious problem in MDS. If you have a low platelet count, it is usually advisable to avoid blood-thinning agents and non-steroidal anti-inflammatory drugs. However, this should be discussed with your doctor as there are exceptions where the benefit you will receive from these drugs outweighs the risks.

Platelets can be transfused but because they only last about four days, they are not routinely given even when the platelet count is very low. But if you have an infection, are on blood thinners or have suffered from bleeding, you might benefit from platelet transfusions to keep your platelet count at a higher level. Your doctor or nurse will inform you when this is necessary.

**Antibiotics**

It is important for you to understand that patients with MDS have a higher risk of developing infections. Antibiotics are not usually given to prevent infections, as they cause side effects and may cause the bacteria to become resistant. But if you do get an infection, this should be treated quickly with antibiotics, and you may need to be admitted into hospital so that the antibiotics can be given through a vein (intravenously). Most specialist units will have a direct phone number to call for advice in the event of a fever occurring.
Treatment of MDS (cont.)

Non-intensive treatment

Low-intensity or non-intensive treatment aims to slow the progression of the disease. It may be considered if your blood counts are quite low or falling, or if there are signs that the disease is developing into leukaemia. The idea is to treat the disease with as few side effects as possible, thereby maintaining a good quality of life. These treatments will not cure your MDS but may ‘modify’ the disease. These treatments are usually given as an outpatient.

Fact sheets for all treatments are available. Please ask your nurse specialist for the correct patient information sheet to help you fully understand your treatment.

Hypomethylating agents (HMA)

Hypomethylating agents work on the behaviour of cancer cells at the DNA level and can turn genes on and off. Drugs such as azacitidine work to improve bone marrow function and slow the progression to leukaemia. They are currently used in high risk MDS patients (IPSS Intermediate-2 and High categories) who are not fit enough for a stem cell transplant. Azacitidine is usually given as an injection under the skin. Side effects can include:

- Mild nausea
- Diarrhoea or constipation
- Skin irritation at the injection site
- Becoming more prone to...
infections (due to lowered blood counts)

**Lenalidomide**

If you have a certain type of MDS which has deletion of part of chromosome 5 (this may be referred to as the 5q minus syndrome or del 5q), you may be offered lenalidomide if you are anaemic. This is taken orally as a capsule and works in several ways to suppress the MDS cells, including altering the immune system. Therefore, it is often referred to as a type of immune modulation therapy. On starting the treatment, your blood counts fall before a response is seen. During this early stage, you may need transfusions of blood and/or platelets. Some patients also need G-CSF. Other side effects can include:

- Rashes
- Fatigue
- Diarrhoea
- A small increased risk of blood clots

As lenalidomide can cause birth defects, you must avoid getting pregnant whilst taking the drug.

**Immunosuppressive therapy**

In a small number of patients with MDS, the number of bone marrow cells is unusually low (termed hypoplastic). This is similar to a blood disease called aplastic anaemia. Patients can sometimes respond to drugs targeted at suppressing the immune system, such as anti-thymocyte globulin (ATG) or ciclosporin.

**Intensive chemotherapy**

If you have high risk MDS, you may benefit from intensive chemotherapy. It is the same treatment that is used to treat acute myeloid leukaemia and aims to kill a significant proportion of the diseased cells from your bone marrow to allow the bone marrow to work normally again (remission). The treatment has a high number of side effects so you need to stay in hospital for four to six weeks for each course.

A small proportion of people may be cured by intensive chemotherapy alone, although usually when a donor is available, a stem cell transplant will follow. Achieving remission, even if not a cure for the disease, can improve your quality of life (often almost to normal quality) as long as the remission lasts.
How is intensive chemotherapy given?

Most chemotherapy is given as an infusion into a vein (intravenously), but sometimes as a tablet. It is given as a course or cycle of treatment, whereby a combination of chemotherapy is given over a number of days followed by a rest period. It is often easier for you to have a Hickman line inserted, which allows all the drugs to be given and blood tests to be taken. This is a line that is carefully inserted into a large vein and can stay in place for the duration of your treatment.

What are the most common side effects from intensive chemotherapy?

The chemotherapy used in MDS is specially designed to kill the cancer cells in the bone marrow, so your blood counts will fall after the chemotherapy and remain low for a number of weeks. Healthy bone marrow cells are also ‘stunned’ in a type of ‘friendly fire’ but can recover better than the MDS cells if remission is achieved. During this time there can be serious, sometimes life-threatening side effects, the most common of which are:

- Infections
- Bleeding
- Anaemia

Other side effects can include:

- Hair loss
- Nausea
- Vomiting
- Sore mouth
- Diarrhoea
- Loss of appetite and taste
- Skin and nail changes
- Infertility

Allogeneic stem cell transplant

A stem cell transplant, also referred to as a bone marrow transplant, offers the chance of curing the disease.

In an allogeneic transplant, healthy bone marrow or stem cells are taken from another person whose tissue DNA is identical or almost identical to yours. This means the donor is compatible with you. The bone marrow or stem cells are taken from a donor – either a family member (usually a sibling) or an unrelated donor.
The donor has a simple blood test to see if they are matched to you – they do not need to have a bone marrow test. The results are usually available in two to three weeks.

As medical knowledge and experience has progressed, more patients can now be considered for a transplant. Reducing the intensity of the conditioning treatment done before the transplant also means the side effects from the transplant itself are less severe. This approach is called a reduced intensity conditioning (RIC) transplant. About one third of patients who receive this treatment are free of disease over many years but the disease may return (relapse).

This treatment has many side effects and it is important that the decision to have an allogeneic stem cell transplant is carefully thought through by your healthcare team and yourself. It is also important to know that the side effects from a stem cell transplant can continue for a number of years after the transplant. If you are suitable for a transplant, you will be referred to a specialist centre to discuss the benefits and risks of this treatment to you as an individual. Always try to take a family member or friend to the appointments.

You can find out more about stem cell transplants in several booklets: ‘The Seven Steps’ booklets, available from Bloodwise and Anthony Nolan, or those from Leukaemia Care.

Follow-up

Once MDS has been diagnosed, your specialist will discuss treatment options and follow-up. For some patients, this will only mean infrequent outpatient visits to check if the disease is showing signs of progressing. Sometimes these check-ups can be shared with the GP. For those patients where the disease is thought to be high risk or for those who have received active treatment, the outpatient visits may be more frequent. This will be individually tailored to you.
This chapter is about the emotional impact of having MDS, which can be as significant as the physical impact of the illness. It is important to emphasise that each person with MDS will cope in their own unique way, and your healthcare team are experienced at considering your emotional needs, as well as your physical needs.

A Holistic Needs Assessment or Quality of Life questionnaire or assessment can often help to identify certain problems, or help discuss them with staff.

Not everything in this chapter will apply to you, but there are some common thoughts and feelings that you could be familiar with – and, to some extent, your relatives and carers too.

**Adjustment**

People living with MDS sometimes experience a range of complex thoughts and intense feelings as they try to cope with the diagnosis, monitoring or treatment. This is often described as ‘being on an emotional rollercoaster’. The formal term for these emotional ups and downs is adjustment.

"The diagnosis hit me like a ton of bricks. My emotions were on a rollercoaster."

Adjustment is something every person will experience as they go through significant life events like divorce, bereavement or illness. It involves changes and losses of varying kinds and includes both practical and mental adjustments. In the case of an illness these include:

- Getting used to being monitored
- Having medical appointments and treatments
- Potential loss of – or reduction in – some physical capabilities which, in turn, could affect things like employment, or personal roles and relationships
- Disruption to one’s usual life patterns and routines
- Questioning things normally taken for granted, like good health and future plans – perhaps making people more worried about things than usual
Given the losses and changes involved – which to some can feel frightening – and the need to adapt to and cope with something new, adjustment can be both stressful and distressing. The good news is, while the emotional ups and downs of adjustment aren’t always easy, with time most people do adapt well to their new situation.

What feelings might you experience and how can you help yourself?

This section describes many of the common emotions (and related thoughts) that people with MDS might experience. Following each description are some suggested coping strategies. These are drawn from evidence-based psychological practices, as well as feedback from patients about what has helped them. It is important to remember that not everyone will experience all of these feelings, but it is equally important to emphasise that if you have some – or all – of them, you are not alone and it is not a sign of weakness or mental health issues.

"The emotions that went through my body cannot be explained – there was anger, worry, fear and sadness. But the overwhelming one was determination that we would get through this."

Coming to terms with your diagnosis

Although everyone is different, generally it is helpful to ‘process’ your thoughts and feelings, rather than ignore them. This means thinking about your diagnosis, including what it means to you and how you might cope. It means being aware of your feelings and being able to express them when you want to. It can be helpful to talk about your situation with other people, both professionals and those in your personal life. Writing thoughts and feelings down can help you to process them too. It is useful to strike a balance between thinking and talking about your situation, and having periods in which you focus on other, meaningful and enjoyable things instead.

"It’s so important to stay positive,
share what's going through your mind and know that you're not alone."

There is a link between thoughts, feelings, physical sensations and behaviour

Before we move on, it is useful to explain that within every type of mood there are four elements: thoughts, feelings, physical sensations and behaviours (the actions we take, or don’t take, to cope). Also, each of these elements interacts with and affects the other, as in this diagram (above).

It is hard to directly ‘access’ and change an emotion, whereas thoughts and behaviours and, to some extent, physical states, are more easily changed. This can help to improve emotional feelings. It is particularly effective to change negative thoughts and thinking patterns. In short, the way we think affects the way we feel.

Managing thoughts

Writing negative thoughts and worries down can be helpful. You will notice that some of them are ‘valid’ (this means understandable and acceptable) given your situation, but some of them are ‘catastrophic’ (meaning they predict the worst case scenario) or are very ‘black and white’ (meaning things are all good or all bad). Here are some examples: “because of this illness, my life’s ruined”; “I know the treatment won’t work”; “nothing ever goes right for me”; “everything’s awful”; “there’s no hope”; “I must be a bad person”. Take a step back and ask yourself whether those thoughts are facts or opinions. Say to yourself “is
there another way of looking at this?”, or "is that actually what my medical team said to me?” Write down alternative, more helpful thoughts next to the original worries. This is not the same as 'positive thinking', as you may have some valid concerns; it is about maintaining perspective, having a balanced view, and not getting too caught up in your thoughts.

"I think at the beginning I did bottle my feelings up too much, trying to stay strong for everyone else."

**Changing behaviour**

Some types of behaviour make emotional distress worse. For example, when people avoid activity, socialising and exercise (even doing basic things like having a shower and getting dressed) they make depression worse, rather than better. And, when people avoid situations that make them anxious, this also tends to make the problem worse, rather than better.

Behavioural change, which includes engaging in enjoyable and meaningful activities, doing even a little exercise, moderating alcohol consumption, and connecting with other people will help your mood. Another helpful behaviour is ‘pacing’. This means doing a consistent amount of activity on a regular basis, but not overextending yourself on a good day. Overextending activities tends to result in people being so exhausted that they cannot function for a few days.

"I have accepted that first thing in the morning I am not going to leap out of bed; my whole body aches so I take it slowly. I feel human and am able to cope with almost anything. I still play golf a couple of times a week, and, being a competitive person I have to remind myself each time how lucky I am just to be out in the sunshine."

**Specific emotions and coping strategies**

**Shock, disbelief, helplessness and feeling out of control**

These feelings and sensations are common when people experience something outside of the realm of their normal experience, like a diagnosis of a serious illness. The situation can feel threatening...
and people wonder whether they can cope. These thoughts and feelings can be so overwhelming that people become shocked or numb as a means of protecting themselves. Some people describe a sense of unreality.

"There was a total overwhelming feeling of helplessness and being out of control of my everyday life. But I had to carry on regardless for everyone else."

Coping strategies

- Time is needed for the information to sink in and to be ‘processed.’

- It can be helpful to talk things through with others and to express feelings. This helps people to make sense of their situation and to think about how they will cope.

- Having access to the right information at this time is important. It can be difficult to take everything in, so it can be useful to write down questions that need answering or clarifying by the healthcare team.

- ‘Grounding’ techniques can be useful. These are simply things people can do to bring their awareness to the reality of the present moment, in other words to feel less detached or unreal. You can find more information on grounding techniques at www.healthyplace.com

"At diagnosis I was shocked and upset. But I was determined to fight it and live a long life."

Worry, anxiety and living with uncertainty

MDS often carries with it a degree of uncertainty which can lead to worry and anxiety. It is normal to experience fear about something which is threatening. The emotional response to fear is anxiety, or even panic. This tends to be driven by the physical response to fear, which is a release of adrenaline into the bloodstream. This leads to many of the physical symptoms of anxiety like increased heart rate and dry mouth. The mental aspect of fear is worry. This is what people do as they try to predict and control things that might happen in the future.
While it is normal for people to worry about their illness to some degree, excessive worry will lead to chronic anxiety and exhaustion.

"I was anxious a lot and focused on my diagnosis and what might happen to me. I didn’t want to die."

Coping strategies

• Managing the physiological part of anxiety is key as this will help to reduce the level of fear and stop the pulse - and thoughts - from racing.

• To do this, it is necessary to reduce hyperventilation (over breathing) and excessive adrenaline production, which are always present in anxiety.

• Slow, controlled breathing is the most effective method. Practices like mindfulness and meditation can be useful, but there are also a number of different breathing exercises that are helpful. For examples of these online, visit www.getselfhelp.co.uk and www.patient.co.uk

• Reducing tension in the muscles is another means of alleviating anxiety.

• A widely-used technique is called ‘progressive muscle relaxation’. This gets people to consciously tense and untense their muscles to induce relaxation.

• Notice your negative thoughts and worries and write them down to challenge them.

• Take gentle exercise.

• Various forms of distraction, or mental exercises like Sudoku, can help.

"Living with uncertainty has been a phrase which I have often used in the past. But living with MDS tests it to extremes. In reality, it’s very difficult to live when you are uncertain what the next few months or years have in store for you. Uncertainty breeds anxiety."

Finally, a vital aspect of managing worry is to accept that some things you cannot know in advance or control. Also, while it is possible to reduce some of the symptoms of anxiety, it is not possible to eliminate them altogether. As human beings we all live with a degree of anxiety. A useful means of managing uncertainty is to focus on the
The psychological impact of MDS (cont.)

‘here and now’ – on the things you can change, and on the things that you find meaningful and enjoyable in the present moment.

Anger
It is common for people to feel angry that they have been diagnosed with a serious illness. For a number of reasons it can feel confusing, unfair, or that it is outside of their control – for example if the illness is rare, if they believe that they have a healthy lifestyle, if there’s no history of similar illnesses in their family, or if they believe that they have already had too many problems in life to cope with. Sometimes it can be difficult to know what to do with feelings of anger or to understand at what the anger is directed. As a result anger can sometimes get directed at loved ones, or even towards oneself.

"At diagnosis I felt distraught, devastated and angry. It was unfair. Why me?"

Coping strategies
- Although a sense of disbelief or injustice at being diagnosed with MDS is valid (and common), dwelling on the thoughts behind it tends to make the anger worse. Talk things through with others.
- Write down some of your thoughts and notice those that keep the anger going; try to change them or distance yourself from thoughts about things that have no explanation or cannot be changed.
- Use relaxation techniques, or exercise, for managing the physiological symptoms of anger (similar to those in anxiety, and also driven by adrenaline).
- ‘Venting’ anger at others tends to be self-defeating because it alienates people, rather than eliciting feelings of compassion from them.
- Self-soothe. Treat yourself to things you enjoy; treat yourself with compassion.

Stress
We experience stress when we feel that we are under too much pressure or have too many demands being made of us and that we don’t have the resources
to cope. Understandably, people can feel like this at times when they are ill and they are trying to cope with the demands of treatment as well as with other concerns, for example financial issues, employment and relationships. The emotional symptoms of stress can include low mood, anxiety and irritability.

Coping strategies

- Relaxation techniques (controlled breathing, progressive muscle relaxation) and/or exercise to manage the physical, adrenaline-fuelled aspects of stress (which are the same as those in anxiety and anger).

- Notice the negative thoughts which contribute to anxiety, tension and irritability, producing adrenaline as they arise: "this is unbearable", "I can’t cope".

- Challenge negative thoughts by writing them down and coming up with more helpful ones e.g. "although this is difficult, I can cope (especially with support)".

- Plan, prioritise, break things down into manageable ‘chunks’ (writing this out is helpful).

- Pace yourself, rather than doing too much or trying to cope with everything at once.

- Take breaks and ‘time out’.

- Ask for help and support.

- Maintain a ‘here and now’ focus on things that are enjoyable and meaningful to you.

Useful online resources include:

- [www.helpguide.org](http://www.helpguide.org)
- [www.getselfhelp.co.uk](http://www.getselfhelp.co.uk)
- [www.nhs.uk/conditions/stress-anxiety-depression](http://www.nhs.uk/conditions/stress-anxiety-depression)

Guilt and blame

Although becoming ill is never anyone’s fault, it is common for people to experience feelings of guilt and blame about their illness. For example people might question whether they became ill because of something they did, or their ‘lifestyle’. Some people might think that they are a burden on other people because they need their help, or because they are not functioning as they once did. Although these thoughts are common, they are not valid. They can be part of people’s attempts to find meaning in the situation,
but what they do is to make people feel bad and distressed about themselves.

"At diagnosis, I felt terror, grief, shock, depression, helplessness."

Coping strategies

- Write guilt and blame thoughts down and try to come up with more balanced and rational thoughts.
- Don’t dwell on these negative thoughts.
- Think about what you would say to a close friend or loved one if they were having these thoughts and feelings - and apply this to yourself.
- Make a conscious effort to be more compassionate towards yourself.
- Do some things which are comforting and soothing.

Sadness, low mood, hopelessness and despair

It is natural and normal for people to experience feelings of intense sadness at times when they are ill. Sometimes it can feel that things aren't going well or that they will never be the same again. Some days people can feel very down, but usually these feelings are temporary and people tend to say that they have ‘good days and bad days’.

However, when people feel persistently sad and hopeless for two weeks or more – and when these feelings are combined with a lack of interest or pleasure in life, disrupted sleep and appetite, feeling worthless, and thinking they would be better off dead, this is not sadness, but depression.

To some extent, sadness, low mood and clinical depression sit along a continuum. At one end, sadness tends to be an appropriate response to a specific situation, which fluctuates and gradually diminishes over time. In the middle, people can have ‘down days’ or ‘feel blue’. At the other end of the spectrum, depression (often called clinical depression) is more severe and persistent, and it affects the whole of a person’s life and stops them from functioning.

Dwelling on negative thoughts is one of the things that makes low mood much worse and keeps it going. Often the thoughts are
self-critical and hopeless in nature; they are nearly always ‘black and white’ or catastrophic. It can be hard to ‘see’ or believe anything positive about life, but all too easy to notice and believe negative things. As with the other emotions, writing down negative thoughts and trying to change them can be helpful, as well as talking things through with others. This helps people to gain some perspective and to feel less hopeless.

"Cancer is such a tough experience and you can easily be filled with very depressing or scary thoughts. Doing something positive is a very good thing."

The other thing that helps depression is doing more and engaging with others. This helps to increase a sense of pleasure and reward from life.

"The support of my family and local community kept me going and talking with them helped me to offload."

Coping strategies

• Activate yourself as much as possible; do more, rather than less. Take gentle exercise and don’t stay in bed or on the sofa.

• Connect with other people.

• Consciously plan and schedule activities, social time and pleasurable things.

• Try to ‘capture’ negative thoughts and come up with more helpful and balanced thoughts.

• Remember to ask yourself: "Is this a fact or an opinion?"; "What's the evidence?"; "Is there another way of seeing this?"; "What would I say to my best friend or partner if they thought this?"

Useful online resources:

• www.getselfhelp.com

• www.nhs.uk/Conditions/stress-anxiety-depression

• www.helpguide.org/articles/depression/dealing-with-depression

Please note: It is often helpful to seek support if you are sad or low in mood, but it is essential to do so if you are depressed, especially if you are having suicidal thoughts. If you are feeling depressed, talk to your GP and to your healthcare team so that they
can organise formal support for you. Talking therapies can help, and medication if necessary.

Grief
Grief is what people experience when they are mourning people, things, or aspects of themselves that they have lost. Grief includes most of the emotions described above, especially sadness, as well as a kind of yearning for what has been lost (in other words, you wish you could have it back). In the case of illness this might include previous roles and responsibilities, previously enjoyed activities, fertility, certain freedoms and choices, health and vitality. As grief is a normal response to loss, it cannot be rationalised away. Loss is something that people can learn to live with – and cope with – over time, especially as they adapt to their changed circumstances and engage with other aspects of life.

Coping strategies
- Although grief is a normal process, a preoccupation with certain types of negative thoughts and beliefs, e.g. “I cannot cope without X, my life isn’t worth living now”, will make it worse and keep it going.
- It can help to write down and challenge thoughts like this.
- It is especially helpful if you can talk about your feelings and about what, or who, has been lost. For a while, many people who are grieving need to be able to ‘tell their stories’ again and again.

Summary
A diagnosis of MDS affects all of you, not just your body. It is common to have a complex mixture of thoughts and feelings. Although this can be unpleasant, this is a normal response to a major life event. Emotional distress of varying kinds can be experienced at any point in your ‘journey’ but it is important to remember there is support out there and ways in which you can help yourself.

Talk to your specialist nurse and reach out to the MDS support groups that are widely available and can help.
Living with MDS – what does this mean to me?

A diagnosis of MDS will have implications for your daily life. Knowing in advance what to expect might alleviate some of the stress or worries around this.

Information about the disease and possible complications can help you recognise when to seek medical attention or ask for further support. It also can give you the feeling that you are more in control.

Hospital visits

A diagnosis of MDS will inevitably involve regular hospital visits. The frequency of these can vary greatly depending on the severity of the symptoms and the progression of the disease. Patients with low risk disease might only need monitoring every few months or even yearly, while others might need weekly checks. Your doctor or nurse will give you guidance on how often visits and blood tests will be needed.

All patients diagnosed with MDS have the right to be referred to a Centre of Excellence for MDS (further details are at the back of this booklet). These are hospitals with expertise in this rare disease and the availability of new drugs via clinical trials. You can ask your doctor if you would benefit from a referral to a Centre of Excellence. You can also ask for an additional opinion if you have questions about your treatment or disease management.

Blood results

Most patients will learn to keep a record of their visits and blood results. There are specially designed diaries or apps for your mobile phone that can help you
record these results. This can be valuable information, especially if you are under the care of more than one hospital or department. Knowing your own blood levels can help you understand why you have certain symptoms and what to do in those situations. You can ask your nurse or doctor to explain the results to you.

The most useful levels to know are:

- Your Hb or haemoglobin (contained in red blood cells) – Hb carries oxygen around your body and is an indicator of whether you are anaemic or not.
- Your platelet count (or thrombocytes) – when these are low you can be prone to bruising or bleeding.
- Your white blood cell count – these are cells that fight infections.
- Your neutrophil count – these cells are a type of white blood cell. Neutrophils are the first line of defence when there is a bacterial infection. When these cells are low, you are said to be neutropenic, and this can make you more susceptible to infections.

**Infection and reducing the risk of infection**

When you are neutropenic (have low levels of neutrophils) and you feel unwell or feverish at home, it is very important to immediately seek medical attention at your nearest hospital. If you are alone or too unwell to leave the house, call an ambulance so that you can be brought to hospital. Patients with the combination of an infection and neutropenia can deteriorate rapidly and should be started on intravenous antibiotics as soon as possible. If you don’t have a thermometer, it is advisable to buy one so that you can measure your temperature when you are at home.

Call your hospital team if your temperature goes above 38°C or you experience shivers (rigors).
Many patients with MDS will be more susceptible to infections, because even if their white cells are not low, they are ‘dysplastic’ and might not work as well as they should. Infections may occur more frequently and also last longer than normal. Patients receiving treatment for their MDS may be more vulnerable to infections especially if the treatment causes a reduction in white cell numbers. Sometimes they are started on drugs to prevent infections.

Good hand hygiene is the best way to avoid catching bacterial infections. There are lots of gels for sale but normal hand washing with water and soap is just as effective. In particular, make sure that you wash your hands after using the toilet, when preparing food, before you eat, and after gardening or touching animals.

Try to avoid people who are unwell and ask your friends and family not to visit when they have cold or flu symptoms.

Normal food hygiene rules apply when you have MDS. When you are on treatment and especially when your neutrophil level drops, you may be asked to avoid certain foods. This varies from one hospital to another. Ask your doctor or nurse for instructions for your specific situation and get general advice from the patient support organisations in this booklet.

When you are planning to travel, ask your doctor if you should take any antibiotics with you, especially if you have experienced picking up infections easily. This may help to avoid any problems while abroad.

If your neutrophil count is low and you have regular infections, you may benefit from injections that can boost your neutrophil levels. G-CSF (granulocyte-colony stimulating factor) is a drug that can be given by injection under the skin. It is a hormone that is normally produced in the body and stimulates the growth of white blood cells in the bone marrow. The injections can cause pain in the bones and muscles which can usually be relieved by taking a mild painkiller, like
paracetamol. You can be taught to give yourself these injections, or a family member, GP or nurse can do it instead.

**Nutrition and exercise**

Eating well and maintaining a healthy weight will give you more strength and energy. A healthy diet includes:

- Lots of fruit and vegetables
- A good proportion of carbohydrates (bread, rice, pasta, potatoes)
- Some protein rich foods (meat, poultry, fish, nuts, eggs, pulses)
- Some dairy products
- Small proportion of foods that are high in salt, fat or sugar
- Plenty of water

You are unlikely to benefit from an increase in iron rich foods as most patients with MDS will have normal or high levels of ferritin (a protein that stores iron) levels. There are many theories about specific diets and cancer. Always discuss with your nurse or doctor before making any changes to your diet.

There is no specific guidance with regards to exercise and MDS. As long as your energy levels allow, you can be as active as you like to be. If your platelets are low, however, you will need to avoid contact sports and be careful with falls or bumps as these may cause serious bleeding.

In general the more active you remain before, during and after treatment, the easier you will recover after having treatment. Some hospitals will provide exercise programs for patients during and after treatment. Ask your nurse or doctor if you want more information about this.

**Fatigue**

Fatigue is one of the most widely reported side effects of low haemoglobin levels. Fatigue or lack of energy can seriously impact on your quality of life. A blood transfusion can improve fatigue temporarily – for some the improvement lasts a few weeks, and for others it may last longer. Treatment for MDS can initially make your fatigue worse but if the
treatment is effective and your blood levels recover, fatigue levels can improve over time.

When you feel fatigued you may find it hard to concentrate or make decisions. The worries of having MDS and dealing with treatment can also add to the feeling of being tired all the time.

Adjusting your lifestyle to your energy levels can be a difficult process. Some general tips on how to deal with fatigue include:

• Have a regular sleep routine – try going to bed and waking up approximately the same time every day and try to avoid lying in.

• Take part in regular, gentle exercise to maintain your fitness levels as much as possible.

• Use ready-made meals if cooking is too tiring, so you keep your energy just for eating.

• Wear clothes that are easy to put on and take off.

• Sit down when doing certain jobs, like ironing or cooking.

• Reserve your energy for what you find important and build rest periods around those times.

• Avoid stimulants before going to bed such as alcohol, coffee, tea or chocolate, or using laptops, tablets or mobile phones.

• Keep your bedroom quiet and at a comfortable temperature.

• Ask for help from family and friends.

• Talk about your worries with family, friends or your doctor or nurse, or patient support groups.

• Discuss your fatigue with your doctor or nurse.

Patient support organisations have booklets, factsheets and videos on managing fatigue. You can find contact details at the back of this booklet. Macmillan Cancer Support has also produced a booklet about fatigue. You can download this at be.macmillan.org.uk
Sexuality and fertility

For some people, sex is an important part of life; for others it might be less important. A diagnosis of MDS can impact your sex life in several ways. For example, you may feel more fatigued and want to reserve your energy for other activities; the treatment sometimes requires you to be admitted to hospital and as a consequence separates you from your partner; you may feel less attractive due to changes to your body, such as hair loss, skin changes or reduction in weight; or your worries may make you feel less interested in sex.

Treatment with chemotherapy can also make sex more difficult as it can cause changes in the mucous membranes resulting in dryness and painful intercourse for women and erectile problems for men.

If you are in a sexual relationship it may help to talk to your partner about the changes you are experiencing and how you are feeling. Your partner may struggle with the subject as well and wait for a sign that you are ready to talk about it. Alternatively, you may want to talk to your GP or nurse who may be able to put you in touch with a sexuality expert or counsellor.

Certain treatments for MDS can have consequences for your fertility, and during some of the treatments you will be asked to take measures to prevent a pregnancy. Lenalidomide is a drug that is NICE approved for a specific group of MDS patients. It can cause birth defects and you will be asked to use contraception during and after this treatment. The same applies for patients that are treated with chemotherapy drugs. Most patients will be permanently infertile after an allogeneic transplant.

Men have the option to freeze their sperm before starting their treatment. If treatment does not need to be started urgently, women also have the option of freezing their eggs. The medical team should discuss these options with you when treatment is required. Do not hesitate to raise these issues yourself if you feel this is important to you.
Changes in sex life and possible infertility may cause a range of difficult feelings. Do speak with someone close to you or your doctor, nurse or counsellor if this is negatively affecting you, and ask for professional support if you feel you need this.

**Work and finances**

MDS and its treatment can sometimes lead to difficulties relating to your work life. Sometimes it leads to temporary sick leave or a reduction in working hours, but it can also mean that you have to stop work altogether. This will most likely have financial consequences for you and your family.

Your consultant can guide you in these decisions and either the hospital or your GP can arrange letters to confirm your situation to your employer. It is often worth taking time to explain MDS to your employer, as it is likely they will never have heard of the disease.

Macmillan Cancer Support has published a booklet about financial support when diagnosed with cancer. They can also give you personal advice over the phone via their helpline and you can discuss which benefits you are eligible for. Some Macmillan centres can arrange face to face meetings with a benefits advisor. Please visit the Macmillan website for more information. They can also provide financial assistance in the form of grants – ask your nurse in the hospital how to apply (see contact details for Macmillan at end of this booklet).

As MDS is regarded as a cancer diagnosis you will also be entitled to apply for a medical exemption certificate which means that you are entitled to free NHS prescriptions. Your GP or specialist nurse at the hospital can provide you with details of how to apply for this. Most hospitals will also have special arrangements for patients on benefits to claim their travel expenses back.

**Extra support at home**

You may find that the MDS or the consequences of the treatment impacts on your independence.
at home. Most patients will have family or friends who can step in when certain tasks or activities need to be taken over, but not everyone will have this kind of support at home.

Speak to your GP if you need additional help at home. They can arrange a social worker to assess your situation and the support that needs to be arranged. When you are in hospital, an occupational therapist can assess your abilities and discuss the support and other resources that you need at home.

**Palliative care**

Some treatments for MDS can cause symptoms that require more than the normal interventions. The palliative care team can provide additional advice and support when symptoms are not easily controlled. Symptoms such as nausea and vomiting, breathlessness and pain are all examples of symptoms regularly dealt with by this specialist team. Their input can be temporary or for a longer period of time, in hospital but also in the community. Some medical treatments can be fairly aggressive and treatments provided by your palliative care team can help you tolerate the side effects of these treatments.

Not all treatments, sadly, are successful and sometimes patients have to be told that the disease is too progressive for any treatment to control it. Discussions around end of life will then be initiated. That conversation will most likely be started by your medical team. Most hospitals will have palliative care teams that have experience in dealing with end of life and related symptom control. Alternatively, you can be referred to a community palliative care team connected with your local hospice. Additional support can be organised either at home, at the hospital or at a hospice in accordance with the wishes of the patient and carer(s).

**Impact of MDS on partners or carers**

As with all cancer diagnoses,
MDS may also have an impact on other members of the family. As MDS is often diagnosed in the elderly, there may be other health issues in the family that require attention.

An initial diagnosis will inevitably cause feelings of concern and anxiety and may cause disruption to the normal life of partners and carers as well. All emotions mentioned earlier in this booklet and information about the psychological impact of MDS may very well also apply to the rest of the family or close friends.

It sometimes happens that the information needs of the patient and the partner differ, where one wants to know more than the other. This can lead to feelings of frustration, misunderstanding or anger. Coping mechanisms may differ too and cause similar feelings.

The support of the partner or carers is very important. Carers who wish to find out more on the disease can contact the organisations involved in this booklet, or Macmillan, who all recognise the important role a carer has in looking after someone with MDS. Carers can also attend support groups in confidence and ask any questions that may help them better understand the needs and care of the person with MDS. Support groups can also help with advice when the need for information differs between carer and patient.

If the responsibility of caring for someone gets too much, respite can be arranged via carers associations. Details of these groups can be found at the back of this booklet.

The Caring for Carers booklet is a great resource to help carers deal with some of the emotions they may face. Available through Leukaemia Care.
There are a number of UK centres with a specialist interest in treating patients with MDS, some of which are recognised as Centres of Excellence.

You can request to be referred to these specialist centres for an additional opinion. The referral request can be made via your GP or your local haematologist. These referrals are particularly helpful for the more complex MDS cases, or if you feel that the care or information you are receiving is not sufficient for your needs.

Please note that additional opinions are sought by many patients across the UK. These are perfectly reasonable requests, given that MDS is a rare and complex disease. Although all haematologists will be familiar with the condition, not all of them will have the specific expertise found in specialist centres.

In general, you should expect your haematologist to provide you with the following:

- Your sub-type of MDS
- Your IPSS or IPSS-R score
- Confirmation that your case was discussed at a regional MDT (multidisciplinary) meeting
- A discussion covering a monitoring/treatment plan
- A mention of the availability of clinical trials
- Regular reviews with potential further biopsy if circumstances change
- Details of a CNS (Clinical Nurse Specialist)
- Information materials and details of support groups

If you do seek an additional opinion at a specialist centre, you will still be treated at your local hospital. Your local haematologist will work together with the specialist to provide you with optimal care. This is called "shared care".

A specialist centre will also provide you with a dedicated Clinical Nurse Specialist, whom you will be able to consult between appointments if necessary.

The specialist centres include:
### England:

<table>
<thead>
<tr>
<th>Hospital</th>
<th>Expertise</th>
</tr>
</thead>
<tbody>
<tr>
<td>King’s College Hospital, London</td>
<td>Professor Ghulam Mufti, Dr Austin Kulasekararaj (international expertise)</td>
</tr>
<tr>
<td>St James’s Institute of Oncology, St. James’s University Hospital, Leeds</td>
<td>Professor David Bowen (international expertise)</td>
</tr>
<tr>
<td>Royal Bournemouth Hospital, Bournemouth</td>
<td>Dr Sally Killick</td>
</tr>
<tr>
<td>Queen Elizabeth Hospital, Birmingham</td>
<td>Professor Charles Craddock, Dr Manoj Raghavan</td>
</tr>
<tr>
<td>Brighton and Sussex University Hospital, Brighton</td>
<td>Dr Tim Chevassut</td>
</tr>
<tr>
<td>MRC Laboratory, Addenbrookes NHS Trust, Cambridge</td>
<td>Professor Alan Warren</td>
</tr>
<tr>
<td>Radcliffe Hospitals and University of Oxford</td>
<td>Professor Paresh Vyas</td>
</tr>
<tr>
<td>The Christie, Manchester</td>
<td>Dr Dan Wiseman</td>
</tr>
<tr>
<td>Northern Centre for Cancer Care, Newcastle</td>
<td>Dr Gail Jones</td>
</tr>
<tr>
<td>Nottingham University Hospital</td>
<td>Dr Rohini Radia</td>
</tr>
<tr>
<td>Great Western Hospital, Swindon</td>
<td>Dr Alex Sternberg</td>
</tr>
<tr>
<td>Royal Cornwall Hospital, Truro</td>
<td>Dr Bryson Pottinger</td>
</tr>
<tr>
<td>Worcestershire Acute Hospitals NHS Trust and Birmingham NHS Foundation Trust</td>
<td>Dr Juliet Mills</td>
</tr>
<tr>
<td>St Bartholomew’s Hospital, London</td>
<td>Professor Jamie Cavenagh</td>
</tr>
<tr>
<td>Northampton General Hospital, Northampton</td>
<td>Dr Jane Parker</td>
</tr>
<tr>
<td>University Hospital Southampton, Southampton</td>
<td>Dr Chris Dalley</td>
</tr>
<tr>
<td>Castle Hill Hospital, Cottingham, Hull</td>
<td>Dr Simone Green</td>
</tr>
</tbody>
</table>

### Scotland:

<table>
<thead>
<tr>
<th>Hospital</th>
<th>Expertise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aberdeen Royal Infirmary, Aberdeen</td>
<td>Dr Dominic Culligan</td>
</tr>
<tr>
<td>Beatson West of Scotland Cancer Centre, Glasgow</td>
<td>Dr Mark Drummond</td>
</tr>
</tbody>
</table>

### Wales:

<table>
<thead>
<tr>
<th>Hospital</th>
<th>Expertise</th>
</tr>
</thead>
<tbody>
<tr>
<td>University Hospital of Wales, Cardiff</td>
<td>Dr Jonathan Kell, Dr Wendy Ingram</td>
</tr>
</tbody>
</table>

### Ireland:

<table>
<thead>
<tr>
<th>Hospital</th>
<th>Expertise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tallaght Hospital, Dublin</td>
<td>Dr Helen Enright</td>
</tr>
</tbody>
</table>
MDS specialist centres and other useful organisations (cont.)

UK patient organisations and support groups

MDS UK (see author information at the beginning of this booklet)
020 7733 7558 (Helpline Mon-Fri 9am - 6pm)
www.mdspatientsupport.org.uk (website and forum)
info@mdspatientsupport.org.uk

Leukaemia Care (see author information at the beginning of this booklet)
08088 010 444 (Freephone helpline open weekdays 9:00am - 10:00pm, Saturdays 9:00am - 12:30pm)
www.leukaemiacare.org.uk
support@leukaemiacare.org.uk

Bloodwise (see author information at the beginning of this booklet)
0808 2080 888
www.bloodwise.org.uk
support@bloodwise.org.uk

MPD Voice
Provides support specifically for those with myeloproliferative disorders
07934 689 354 (Monday - Friday between 8am & 5pm)
www.mpdvoice.org.uk
info@mpdvoice.org.uk

Macmillan Cancer Support
Provides a helpline, information on all types of cancer, financial advice and travel insurance recommendations.
0808 808 00 00
www.macmillan.org.uk

Anthony Nolan
Provides information specifically to patients, families and stem cell donors regarding stem cell transplantation and donation.
0303 303 0303
www.anthonynolan.org
info@anthonynolan.org

Maggie’s Centres
Maggie’s offers free practical,
emotional and social support to people with cancer and their families.

www.maggiescentres.org

**International patient organisations and support groups**

**MDS Support Group Ireland (& Northern Ireland)**
086 200 1402
disireland7@gmail.com

**MDS Foundation**
International information and support group based in the USA. Provides further information on MDS - and contact with American MDS patients via a chat forum.

www.mds-foundation.org
patientliaison@mds-foundation.org

**Aplastic Anaemia and MDS International Foundation**
International organisation, based in the USA, supporting patients and families living with aplastic anaemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal haemoglobinuria (PNH), and related bone marrow failure diseases.

www.aamds.org
help@AAMDS.org

**Other MDS resources**

**MDS-Europe**
The website for the MDS-RIGHT programme in Europe now hosting MDS blogs, international patient resources (including UK) and interactive MDS guidelines for diagnosis and management

www.mds-europe.org

**Financial assistance and benefits advice**

**Macmillan Cancer Support**
0808 808 00 00

**Your local Citizens Advice Bureau**
www.adviceguide.org.uk

**Turn2us**
0808 802 2000
## MDS specialist centres and other useful organisations (cont.)

<table>
<thead>
<tr>
<th><a href="http://www.turn2us.org.uk">www.turn2us.org.uk</a></th>
<th><a href="http://www.carers.org">www.carers.org</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Travel insurance</strong></td>
<td><a href="mailto:support@carers.org">support@carers.org</a></td>
</tr>
</tbody>
</table>

Whilst it can often be difficult to get travel insurance if you have a pre-existing medical condition such as MDS, you can still go on holiday.

Fact sheets and information about travel insurance and recommended insurance providers are available from MDS UK and Leukaemia Care.

### For carers

**Carers UK**

0808 808 7777

www.carersuk.org

info@carersuk.org

**Carers Trust**

0844 800 4361
**Acute Myeloid Leukaemia (AML)**
AML is a cancer of the blood and bone marrow. It is characterised by an increase in the number of myeloid cells in the marrow that do not mature and interfere with the production of healthy blood cells.

**Allogeneic stem cell transplant**
A procedure where bone marrow stem cells are taken from a genetically matched donor and given to the patient through an intravenous (IV) line. The donor may be related or unrelated.

**Anaemia**
A medical condition in which the red blood cell count or haemoglobin is less than normal. On a normal blood result, RBC will show as approx: Red Blood Count (RBC) Males: 4.5-6.5; Females 3.8-5.8 - 1012/L

**Blast cell**
An abnormal (dysplastic), immature blood cell found in the bone marrow or peripheral blood. As they are not mature, these cells are unable to fulfil their intended function. AML develops from these blast cells.

**Blood transfusion**
A procedure in which whole blood or one of its components is given to a person through an intravenous (IV) line into the bloodstream. A red blood cell transfusion or a platelet transfusion can help some patients with low blood counts.

**Bone marrow**
The soft blood-forming tissue that fills the cavities of bones and contains fat, immature and mature blood cells, including white blood cells, red blood cells, and platelets.

**Chemotherapy**
Therapy for cancer using chemicals that stop the growth of cells.

**Clinical trial**
A medical research study involving patients with the aim of improving treatments and their side effects. You will always be informed if your treatment is part of a trial.

**Cytogenetics**
The study of chromosomes (DNA), the part of the cell that contains genetic information. Some cytogenetic abnormalities are linked to different forms of myelodysplastic syndromes (MDS).
Fatigue
Extreme tiredness, which is not alleviated by sleep or rest. Fatigue can be acute and come on suddenly or it can be chronic and persistent.

Full blood count or FBC
A blood test that counts the number of different blood cells.

Genomics
The study of genes and their functions, which is increasingly important to refine the prognosis of the various sub-types of MDS. In future this information may also help to personalise MDS treatments.

Haemoglobin
A protein in the red blood cells. Haemoglobin picks up oxygen in the lungs and brings it to cells in all parts of the body. Normal counts are approx: Haemoglobin (HB) Males 130-180; Females 115-165 g/L

Neutropenia
A condition in which the number of neutrophils (a type of white blood cell) in the bloodstream is decreased.

Neutrophil
A type of white blood cell that helps fight infection.

Platelet
A disc-shaped element in the blood that assists in blood clotting. During normal blood clotting, the platelets clump together (aggregate). Although platelets are often classed as blood cells, they are actually fragments of large bone marrow cells (megakaryocytes).

Platelet count
A normal platelet count in a healthy individual is between 150,000 and 450,000 per microlitre of blood. In general, low platelet counts increase bleeding risks. Normal platelet Count (PLT) 150-450 - 109/L

Stem cells
Cells that have the potential to develop into many different or specialised cell types.

White blood cell
One of the cells the body makes to help fight infections. There are several types of white blood cells. The two most common types are the lymphocytes and neutrophils. Normal White Cell Count (WBC) 4-11 - 109/L
Appendix

International Prognostic Scoring System for MDS

The International Prognostic Scoring System (IPSS) was developed by analysing information on almost 1,000 MDS patients, who mostly received only supportive care, and determining which factors best predicted disease progression and outcome. This was then used to create a scoring system based on percentage of blasts in the bone marrow, cytogenetics and the number of cell types affected in the circulating blood. The IPSS is now only used to decide whether patients are suitable for certain treatments that were developed in the IPSS era (1995-2012). Since 2012, all discussions with patients about prognosis should be based on the IPSS-R:

The Revised IPSS (IPSS-R)

This scoring system has used the data gathered from patients in the IPSS to further categorise patients into more defined risk groups from over 7,000 untreated patients with MDS. The score now has five categories which allow a more accurate idea of expected outcome.

Both scoring systems should only be used at diagnosis and not during the course of the disease.

IPSS-R Cytogenetic Prognostic Subgroups

The cytogenetic result from the patient’s bone marrow sample is an important part of the IPSS-R score. The table below shows cytogenetic risk categories:

<table>
<thead>
<tr>
<th>Cytogenetic category</th>
<th>Cytogenetic abnormalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very good</td>
<td>-Y, del(11q)</td>
</tr>
<tr>
<td>Good</td>
<td>Normal, del(5q), del(12p), del(20q), double including del(5q)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>del(7q), +8, +19, i(17q), any other single or double independent clones</td>
</tr>
</tbody>
</table>
Appendix (cont.)

IPSS-R Prognostic Score Values (below)

To calculate a person’s prognostic score, we use the variables in the left hand column. Each variable has a number or ‘score’ between 0 and 4. The numbers are then added together to give your final IPSS-R score.

<table>
<thead>
<tr>
<th>Prognostic variable</th>
<th>0</th>
<th>0.5</th>
<th>1</th>
<th>1.5</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytogenetics</td>
<td>Very Good</td>
<td>Good</td>
<td>Intermediate</td>
<td>Poor</td>
<td>Very Poor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow blast %</td>
<td>≤2</td>
<td>&gt;2-&lt;5</td>
<td>5-10</td>
<td>&gt;10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemoglobin concentration (g/l)</td>
<td>≥100</td>
<td>80-&lt;100</td>
<td>&lt;80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platelet count (x 10⁹/l)</td>
<td>≥100</td>
<td>50-&lt;100</td>
<td>&lt;50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophil count (x 10⁹/l)</td>
<td>≥0.8</td>
<td>&lt;0.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**IPSS-R Prognostic Risk Categories/Scores and Clinical Outcomes**

The table below shows what the predicted clinical outcomes for people with MDS in different risk groups are.

<table>
<thead>
<tr>
<th>Risk category</th>
<th>Risk score</th>
<th>Survival (median – years**)</th>
<th>25% AML evolution* (median – years**)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very Low</td>
<td>≤1.5</td>
<td>8.8</td>
<td>NR</td>
</tr>
<tr>
<td>Low</td>
<td>&gt;1.5-3</td>
<td>5.3</td>
<td>10.8</td>
</tr>
<tr>
<td>Intermediate</td>
<td>&gt;3-4.5</td>
<td>3.0</td>
<td>3.2</td>
</tr>
<tr>
<td>High</td>
<td>&gt;4.5-6</td>
<td>1.6</td>
<td>1.4</td>
</tr>
<tr>
<td>Very High</td>
<td>&gt;6</td>
<td>0.8</td>
<td>0.73</td>
</tr>
</tbody>
</table>

* This column (25% AML evolution) is the average length of time that it would take for one quarter of patients to develop AML in that IPSS-R group.

** median = The midpoint of data after being ranked from lowest to highest. It shows that for the 25% of patients who do progress to AML, half of them would progress before this time period and half of them after it.
Definitions used in the IPSS

Karyotype (cytogenetic abnormalities)
- Good – normal, deletion of Y chromosome, del(5q), del(20q)
- Poor – complex (more than 3 abnormalities), chromosome 7 abnormalities
- Intermediate – all other abnormalities

Cytopenias (low blood counts)
- Haemoglobin – less than 100g/l (or 10g/dl)
- Neutrophils – less than 1.8 x 10^9/l
- Platelets – less than 100 x 10^9/l

IPSS score table

<table>
<thead>
<tr>
<th>Score</th>
<th>0</th>
<th>0.5</th>
<th>1</th>
<th>1.5</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of blasts in the bone marrow</td>
<td>&lt;5</td>
<td>5-10</td>
<td>11-20</td>
<td>21-30</td>
<td></td>
</tr>
<tr>
<td>Karyotype</td>
<td>Good</td>
<td>Intermediate</td>
<td>Poor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of cytopenias</td>
<td>0/1</td>
<td>2/3</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The individual scores for bone marrow blast percentage, karyotype and cytopenias are added together to give the IPSS score. The scores for the risk groups are as follows:

<table>
<thead>
<tr>
<th>Risk Group</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk</td>
<td>0</td>
</tr>
<tr>
<td>INT-1 risk</td>
<td>0.5-1.0</td>
</tr>
<tr>
<td>INT-2 risk</td>
<td>1.5-2.0</td>
</tr>
<tr>
<td>High risk</td>
<td>&gt;2.5</td>
</tr>
<tr>
<td>World Health Organization (WHO) 2008 Classification (for updated 2016 version, see section 5)</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>• Refractory cytopenia with unilineage dysplasia (RCUD)</td>
<td></td>
</tr>
<tr>
<td>• Refractory anaemia with ring sideroblasts (RARS)</td>
<td></td>
</tr>
<tr>
<td>• Refractory cytopenia with multilineage dysplasia (RCMD)</td>
<td></td>
</tr>
<tr>
<td>• Refractory anaemia with excess blasts (RAEB)</td>
<td></td>
</tr>
<tr>
<td>• Myelodysplastic syndrome unclassified (MDS-U)</td>
<td></td>
</tr>
<tr>
<td>• MDS associated with del(5q), including the 5q- syndrome</td>
<td></td>
</tr>
</tbody>
</table>

**Tell us what you think!**

If you would like to give us some feedback about this patient information booklet, please hover over the code to the right using your phone or tablet’s camera. Click the link as it appears and this will take you to a short web form to fill in.

Suitable for Android, iPhone 7 and above.
Leukaemia Care is a national charity dedicated to providing information, advice and support to anyone affected by a blood cancer.

Around 34,000 new cases of blood cancer are diagnosed in the UK each year. We are here to support you, whether you’re a patient, carer or family member.

Want to talk?

Helpline: **08088 010 444**
(free from landlines and all major mobile networks)

Office Line: **01905 755977**

www.leukaemiacare.org.uk

support@leukaemiacare.org.uk

Leukaemia Care,
One Birch Court,
Blackpole East,
Worcester,
WR3 8SG

Registered charity
259483 and SC039207